Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact:
Sheree Aronson
VP, Investor Relations
(949) 367-9600 ext 371
saronson@glaukos.com
Glaukos Corporation Announces First Quarter 2016 Financial Results
Company Raises 2016 Net Sales Guidance
Laguna Hills, CA — May 3, 2016 — Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the first quarter ended March 31, 2016. Key highlights include:
· Achieved 57% net sales growth to $23.1 million in the first quarter of 2016, compared to $14.7 million in the first quarter of 2015
· Expanded gross margin to 86% in the first quarter of 2016, compared to 81% in the first quarter of 2015
· Reported net income attributable to Glaukos Corporation of $897,000, or $0.03 per diluted share, in the first quarter of 2016, compared to a net loss attributable to Glaukos Corporation of $966,000, or a loss of $0.40 per diluted share, in the first quarter of 2015
· Raised 2016 net sales guidance to a range of $100 million to $102 million from prior guidance range of $90 million to $93 million
“Glaukos is off to an exceptional start in 2016 with solid first quarter performance driven by the continuing success of our flagship micro-scale glaucoma device, the iStent® Trabecular Micro-Bypass Stent,” said Thomas Burns, president and chief executive officer of Glaukos. “We are leveraging our seasoned sales organization and growing body of compelling clinical evidence to deliver sustained sales growth, while advancing a deep pipeline of glaucoma technologies designed to address the full range of glaucoma disease states and progression.”
First Quarter 2016 Financial Results
Net sales rose 57% in the first quarter of 2016 to $23.1 million, compared to $14.7 million in the same period in 2015. The growth reflected primarily increased iStent utilization across the company’s expanding customer base.
1
Gross margin for the first quarter of 2016 rose to approximately 86%, compared to approximately 81% in the same period in 2015. The company’s ability to leverage its fixed manufacturing costs and intangible amortization against higher sales contributed to the increase in gross margin in the first quarter, along with the 2016-2017 suspension of the medical device excise tax under the PATH (Protecting Americans from Tax Hikes) Act. Additionally, sales of iStent inject® Trabecular Micro-Bypass Stent in Australia and Canada in the first quarter of 2016 had no associated cost of sales, as the manufacturing costs had been charged to R&D expense in 2015, prior to commercial launch in these countries.
Operating expenses for the first quarter of 2016 were $19.4 million, up 48% compared to $13.1 million in the same period of 2015. The increase was due primarily to higher personnel, travel and other costs associated with the ongoing expansion of the company’s global infrastructure and sales organization.
Income from operations was $621,000 in the first quarter of 2016, compared to a loss from operations of $1.2 million in the first quarter of 2015. Net income attributable to Glaukos Corporation in the first quarter of 2016 was $897,000, compared to a net loss attributable to Glaukos Corporation of $966,000 in the same period one year ago. Diluted net income per share for the first quarter of 2016 was $0.03, compared to a diluted net loss per share of $0.40 in the first quarter of 2015.
2016 Revenue Guidance
The company raised its 2016 net sales guidance to a range of $100 million to $102 million versus prior guidance of $90 million to $93 million. The revised guidance implies growth in 2016 net sales of approximately 39% to 42%, compared to 2015.
Webcast & Conference Call
The company will host a conference call and simultaneous webcast today at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss the results. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 877-201-0168 (U.S.) or 647-788-4901 (international) and enter Conference ID 88498885. A replay of the webcast will be archived on the company’s website immediately following completion of the call and will be available until August 3, 2016.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.
2
Forward-Looking Statements
All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties include, without limitation, uncertainties about our ability to maintain profitability; our dependence on the success and market acceptance of the iStent; our ability to leverage our sales and marketing infrastructure to increase market penetration and acceptance of our products; our dependence on a limited number of third-party suppliers for components of our products; the occurrence of a crippling accident or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; maintaining adequate coverage or reimbursement by third-party payors for procedures using the iStent or other products in development; our ability to properly train, and gain acceptance and trust from, ophthalmic surgeons in the use of our products; our ability to successfully develop and commercialize additional products; our ability to compete effectively in the highly competitive and rapidly changing medical device industry and against current and future competitors (including MIGS competitors) that are large public companies or divisions of publicly traded companies that have competitive advantages; the timing, effect and expense of navigating different regulatory approval processes as we develop additional products and penetrate foreign markets; the effect of the extensive and increasing federal and state regulation in the healthcare industry on us and our suppliers; the lengthy and expensive clinical trial process and the uncertainty of outcomes from any particular clinical trial; our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors that could develop and commercialize similar or identical products; the impact of any claims against us of infringement or misappropriation of third party intellectual property rights and any related litigation; and the market’s perception of our limited operating history as a public company. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which we expect to file on or before May 6, 2016. Our filings with the Securities and Exchange Commission are available in the Investor section of our website at www.glaukos.com or at www.sec.gov. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
3
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)
| | Three Months Ended
March 31, | |
| | 2016 | | 2015 | |
Net sales | | $ | 23,092 | | $ | 14,666 | |
Cost of sales | | 3,121 | | 2,794 | |
Gross profit | | 19,971 | | 11,872 | |
Operating expenses: | | | | | |
Selling, general and administrative | | 12,288 | | 7,816 | |
Research and development | | 7,062 | | 5,240 | |
Total operating expenses | | 19,350 | | 13,056 | |
Income (loss) from operations | | 621 | | (1,184 | ) |
Other income (expense), net | | | | | |
Interest and other income | | 335 | | — | |
Interest and other expense, net | | (102 | ) | (269 | ) |
Change in fair value of stock warrant liability | | 43 | | (9 | ) |
Total other income (expense), net | | 276 | | (278 | ) |
Income (loss) before taxes | | 897 | | (1,462 | ) |
Provision for income taxes | | — | | — | |
Net income (loss) | | 897 | | (1,462 | ) |
Net loss attributable to noncontrolling interest | | — | | (496 | ) |
Net income (loss) attributable to Glaukos Corporation | | $ | 897 | | $ | (966 | ) |
Basic net income (loss) per share attributable to Glaukos Corporation stockholders | | $ | 0.03 | | $ | (0.40 | ) |
Diluted net income (loss) per share attributable to Glaukos Corporation stockholders | | $ | 0.03 | | $ | (0.40 | ) |
Weighted average shares used to compute basic net income (loss) per share attributable to Glaukos Corporation stockholders | | 32,317 | | 2,410 | |
Weighted average shares used to compute diluted net income (loss) per share attributable to Glaukos Corporation stockholders | | 35,724 | | 2,410 | |
4
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par values)
| | March 31, | | December 31, | |
| | 2016 | | 2015 | |
| | (unaudited) | | | |
Assets | | | | | |
Current assets: | | | | | |
Cash and cash equivalents | | $ | 10,392 | | $ | 21,572 | |
Short-term investments | | 77,848 | | 69,552 | |
Accounts receivable, net | | 9,569 | | 7,549 | |
Inventory | | 5,061 | | 4,097 | |
Prepaid expenses and other current assets | | 1,653 | | 1,290 | |
Restricted cash | | 80 | | 80 | |
Total current assets | | 104,603 | | 104,140 | |
Property and equipment, net | | 2,259 | | 2,154 | |
Intangible assets, net | | 9,305 | | 10,218 | |
Deposits and other assets | | 150 | | 149 | |
Total assets | | $ | 116,317 | | $ | 116,661 | |
| | | | | |
Liabilities and stockholders’ equity | | | | | |
Current liabilities: | | | | | |
Accounts payable | | $ | 3,584 | | $ | 3,626 | |
Accrued liabilities | | 6,901 | | 7,793 | |
Long-term debt, current portion | | 7,504 | | 8,931 | |
Deferred rent | | — | | 12 | |
Total current liabilities | | 17,989 | | 20,362 | |
Long-term debt, less current portion | | — | | 765 | |
Stock warrant liability | | — | | 105 | |
Other liabilities | | 269 | | 238 | |
Total liabilities | | 18,258 | | 21,470 | |
| | | | | |
Stockholders’ equity: | | | | | |
Preferred stock, $0.001 par value; 5,000 authorized at March 31, 2016 and December 31, 2015; no shares issued and outstanding at March 31, 2016 and December 31, 2015 | | — | | — | |
Common stock, $0.001 par value; 150,000 authorized at March 31, 2016 and December 31, 2015; 32,397 and 32,209 shares issued and 32,369 and 32,181 shares outstanding at March 31, 2016 and December 31, 2015, respectively | | 32 | | 32 | |
Additional paid-in capital | | 293,841 | | 291,853 | |
Accumulated other comprehensive income | | 34 | | 51 | |
Accumulated deficit | | (195,716 | ) | (196,613 | ) |
| | 98,191 | | 95,323 | |
Less treasury stock (28 shares as of March 31, 2016 and December 31, 2015) | | (132 | ) | (132 | ) |
Total stockholders’ equity | | 98,059 | | 95,191 | |
Total liabilities and stockholders’ equity | | $ | 116,317 | | $ | 116,661 | |
###
5
